POLQ inhibition also enhances PARP inhibitor effectiveness and activates the cGAS-STING pathway in an HRD pancreatic adenocarcinoma mouse model, suggesting that it may have applications in ICB immunotherapy, in which STING agonists are also under investigation [253]. The gene discussed is STING1; the disease is pancreatic adenocarcinoma.